Dr Olivia Dean

STAFF PROFILE

Position

Senior Lecturer in Medical Sciences

Faculty

Faculty of Health

Department

School of Medicine

Campus

Geelong Waurn Ponds Campus

Contact

o.dean@deakin.edu.au
+61342153300

Publications

Filter by

2017

A potential role for N-acetylcysteine in the management of methamphetamine dependence

R McKetin, O Dean, A Baker, G Carter, A Turner, P Kelly, M Berk

(2017), Vol. 36, pp. 153-159, Drug and alcohol review, London, Eng., C1

journal

Beyond the therapeutic shackles of the monoamines: new mechanisms in bipolar disorder biology

J Data-Franco, A Singh, D Popovic, M Ashton, M Berk, E Vieta, M Figueira, O Dean

(2017), Vol. 72, pp. 73-86, Progress in neuro-psychopharmacology & biological psychiatry, Amsterdam, The Netherlands, C1

journal

Cognitive effects of adjunctive N-acetyl cysteine in psychosis

M Rapado-Castro, S Dodd, A Bush, G Malhi, D Skvarc, Z On, M Berk, O Dean

(2017), Vol. 47, pp. 866-876, Psychological medicine, Cambridge, Eng., C1

journal

A model of the mitochondrial basis of bipolar disorder

G Morris, K Walder, S McGee, O Dean, S Tye, M Maes, M Berk

(2017), Vol. 74, pp. 1-20, Neuroscience and biobehavioral reviews, Amsterdam, The Netherlands, C1

journal

A randomised controlled trial of dietary improvement for adults with major depression (the 'SMILES' trial)

F Jacka, A O'Neil, R Opie, C Itsiopoulos, S Cotton, M Mohebbi, D Castle, S Dash, C Mihalopoulos, M Chatterton, L Brazionis, O Dean, A Hodge, M Berk

(2017), Vol. 15, pp. 1-13, BMC medicine, London, Eng., C1

journal

A review of the theoretical and biological understanding of the nocebo and placebo phenomena

S Dodd, O Dean, J Vian, M Berk

(2017), Vol. 39, pp. 469-476, Clinical therapeutics, Amsterdam, The Netherlands, C1

journal

Adjunctive N-acetylcysteine in depression: exploration of interleukin-6, C-reactive protein and brain-derived neurotrophic factor

K Hasebe, L Gray, C Bortolasci, B Panizzutti, M Mohebbi, S Kidnapillai, B Spolding, K Walder, M Berk, G Malhi, S Dodd, O Dean

(2017), pp. 1-10, Acta neuropsychiatrica, Cambridge, Eng., C1

journal

The efficacy of sodium benzoate as an adjunctive treatment in early psychosis - Cadence-BZ: study protocol for a randomized controlled trial

A Ryan, A Baker, F Dark, S Foley, A Gordon, S Hatherill, S Stathis, S Saha, G Bruxner, M Beckman, D Richardson, M Berk, O Dean, J McGrath, Cadence Working Group, J Scott

(2017), Vol. 18, pp. 1-11, Trials, London, Eng., C1

journal

the effect of n-acetylcysteine (nac) on human cognition - a systematic review

D Skvarc, O Dean, L Byrne, L Gray, S Lane, M Lewis, B Fernandes, M Berk, A Marriott

(2017), Vol. 78, pp. 44-56, Neuroscience & Biobehavioral Reviews, Amsterdam, The Netherlands, C1

journal

Adjunctive minocycline treatment for major depressive disorder: a proof of concept trial

O Dean, B Kanchanatawan, M Ashton, M Mohebbi, C Ng, M Maes, L Berk, A Sughondhabirom, S Tangwongchai, A Singh, H McKenzie, D Smith, G Malhi, N Dowling, M Berk

(2017), Vol. 51, pp. 829-840, Australian & New Zealand journal of psychiatry, London, Eng., C1

journal
2016

C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications

B Fernandes, J Steiner, H Bernstein, S Dodd, J Pasco, O Dean, P Nardin, C Gonçalves, M Berk

(2016), Vol. 21, pp. 554-564, Molecular psychiatry, London, Eng., C1

journal

A review of vulnerability and risks for schizophrenia: beyond the two hit hypothesis

J Davis, H Eyre, F Jacka, S Dodd, O Dean, S McEwen, M Debnath, J McGrath, M Maes, P Amminger, P McGorry, C Pantelis, M Berk

(2016), Vol. 65, pp. 185-194, Neuroscience & biobehavioral reviews, Amsterdam, The Netherlands, C1

journal

Antioxidant treatments for schizophrenia

P Magalhães, O Dean, A Andreazza, M Berk, F Kapczinski

(2016), Vol. 2016, pp. 1-93, Cochrane database of systematic reviews, London, Eng., C1

journal

N-Acetylcysteine in depressive symptoms and functionality: a systematic review and meta-analysis

B Fernandes, O Dean, S Dodd, G Malhi, M Berk

(2016), Vol. 77, pp. 457-466, Journal of clinical psychiatry, Memphis, Tenn., C1

journal

A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder

O Dean, K Gray, K-A Villagonzalo, S Dodd, M Mohebbi, T Vick, B Tonge, M Berk

(2016), Vol. 51, pp. 1-9, Australian and New Zealand journal of psychiatry, London, Eng., C1

journal

The Post-Anaesthesia N-acetylcysteine Cognitive Evaluation (PANACEA) trial: study protocol for a randomised controlled trial

D Skvarc, O Dean, L Byrne, L Gray, K Ives, S Lane, M Lewis, C Osborne, R Page, D Stupart, A Turner, M Berk, A Marriott

(2016), Vol. 17, pp. 1-11, Trials, London, Eng., C1

journal

N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms

S Rossell, P Francis, C Galletly, A Harris, D Siskind, M Berk, K Bozaoglu, F Dark, O Dean, D Liu, D Meyer, E Neill, A Phillipou, J Sarris, D Castle

(2016), Vol. 16, pp. 1-9, BMC psychiatry, London, Eng., C1

journal

Participant characteristics as modifiers of response to N-Acetyl cysteine (NAC) in obsessive-compulsive disorder

J Sarris, G Oliver, D Camfield, O Dean

(2016), Vol. 4, pp. 1104-1111, Clinical psychological science, London, Eng., C1

journal
2015

Towards stage specific treatments: Effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia.

M Rapado-Castro, M Berk, K Venugopal, A Bush, S Dodd, O Dean

(2015), Vol. 57, pp. 69-75, Progress in Neuro-Psychopharmacology and Biological Psychiatry, Amsterdam, The Netherlands, C1

journal

Oxidative stress and post-stroke depression: possible therapeutic role of polyphenols?

S Nabavi, O Dean, A Turner, A Sureda, M Daglia, S Nabavi

(2015), Vol. 22, pp. 343-351, Current medicinal chemistry, Beijing, China, C1-1

journal

Tobacco use in bipolar disorder.

D Thomson, M Berk, S Dodd, M Rapado-Castro, S Quirk, P Ellegaard, L Berk, O Dean

(2015), Vol. 13, pp. 1-11, Clinical Psychopharmacology and Neuroscience, Korea (South), C1

journal

N-acetyl cysteine in the treatment of obsessive compulsive and related disorders: a systematic review

G Oliver, O Dean, D Camfield, S Blair-West, C Ng, M Berk, J Sarris

(2015), Vol. 13, pp. 12-24, Clinical psychopharmacology and neuroscience, Korea (South), C1

journal

Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review.

Deepmala, J Slattery, N Kumar, L Delhey, M Berk, O Dean, C Spielholz, R Frye

(2015), Vol. 55, pp. 294-321, Neuroscience and Biobehavioral Reviews, Amsterdam, The Netherlands, C1

journal

N-Acetyl Cysteine (NAC) in the treatment of obsessive-compulsive disorder: a 16-week, double-blind, randomised, placebo-controlled study

J Sarris, G Oliver, D Camfield, O Dean, N Dowling, D Smith, J Murphy, R Menon, M Berk, S Blair-West, C Ng

(2015), Vol. 29, pp. 801-809, CNS Drugs, Berlin, Germany, C1

journal

Future directions for pharmacotherapies for treatment-resistant bipolar disorder

S Dodd, B Simoes Fernandes, O Dean

(2015), Vol. 13, pp. 656-662, Current neuropharmacology, Bussum, The Netherlands, C1

journal

Youth Depression Alleviation-Augmentation with an anti-inflammatory agent (YoDA-A): protocol and rationale for a placebo-controlled randomized trial of rosuvastatin and aspirin.

A Quinn, O Dean, C Davey, M Kerr, S Harrigan, S Cotton, A Chanen, S Dodd, A Ratheesh, G Amminger, M Phelan, A Williams, A Mackinnon, F Giorlando, S Baird, S Rice, M O'Shea, M Schäfer, E Mullen, S Hetrick, P McGorry, M Berk

(2015), pp. 1-10, Early intervention in psychiatry, London, Eng., C1

journal

The use of mixed methods in drug discovery: integrating qualitative methods into clinical trials

M Berk, R Otmar, O Dean, L Berk, E Michalak

(2015), pp. 59-73, Clinical trial design challenges in mood disorders, Amsterdam, The Netherlands, B1

chapter
2014

Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: therapeutic implications

G Anderson, M Berk, O Dean, S Moylan, M Maes

(2014), Vol. 28, CNS Drugs, Aukland, New Zealand, C1

journal

Post-stroke depression therapy: where are we now?

S Nabavi, A Turner, O Dean, A Sureda, S Nabavi

(2014), Vol. 11, pp. 1-13, Current neurovascular research, Bussum, The Netherlands, C1

journal

The efficacy of adjunctive N-Acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial

M Berk, O Dean, S Cotton, S Jeavons, M Tanious, K Kohlmann, K Hewitt, K Moss, C Allwang, I Schapkaitz, J Robbins, H Cobb, F Ng, S Dodd, A Bush, G Malhi

(2014), Vol. 75, pp. 628-636, Journal of clinical psychiatry, Memphis, Tenn., C1

journal

Oxidative & nitrosative stress in depression: why so much stress?

S Moylan, M Berk, O Dean, Y Samuni, L Williams, A O'Neil, A Hayley, J Pasco, G Anderson, F Jacka, M Maes

(2014), Vol. 45, pp. 46-62, Neuroscience and biobehavioral reviews, Amsterdam, The Netherlands, C1

journal

Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression

O Dean, A Turner, G Malhi, C Ng, S Cotton, S Dodd, J Sarris, Y Samuni, M Tanious, N Dowling, A Waterdrinker, D Smith, M Berk

(2014), Vol. 0, pp. 1-10, Revista Brasileira de psiquiatria, Sao Paulo, Brazil, C1

journal

The Glutathione System: a new drug target in neuroimmune disorders

G Morris, G Morris, G Anderson, G Anderson, O Dean, O Dean, M Berk, M Berk, P Galecki, P Galecki, M Martin-Subero, M Martin-Subero, M Maes, M Maes

(2014), Vol. 50, pp. 1059-1084, Molecular neurobiology, New York, N. Y., C1

journal

The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): study protocol for a randomised control trial.

C Davey, A Chanen, S Cotton, S Hetrick, M Kerr, M Berk, O Dean, K Yuen, M Phelan, A Ratheesh, M Schäfer, G Amminger, A Parker, D Piskulic, S Harrigan, A Mackinnon, B Harrison, P McGorry

(2014), Vol. 15, pp. 1-9, Trials, London, Eng., C1

journal

Protocol and Rationale-The Efficacy of Minocycline as an Adjunctive Treatment for Major Depressive Disorder: A Double Blind, Randomised, Placebo Controlled Trial.

O Dean, M Maes, M Ashton, L Berk, B Kanchanatawan, A Sughondhabirom, S Tangwongchai, C Ng, N Dowling, G Malhi, M Berk

(2014), Vol. 12, pp. 180-188, Clinical psychopharmacology and neuroscience, Seoul, Korea, C1

journal
2013

Putative neuroprotective agents in neuropsychiatric disorders

S Dodd, M Maes, G Anderson, O Dean, S Moylan, M Berk

(2013), Vol. 42, pp. 135-145, Progress in neuro-psychopharmacology and biological psychiatry, United States, C1

journal

The promise of N-acetylcysteine in neuropsychiatry

M Berk, G Malhi, L Gray, O Dean

(2013), Vol. 34, pp. 167-177, Trends in pharmacological sciences, Oxford, England, C1

journal

Metabolite profiles in the anterior cingulate cortex of depressed patients differentiate those taking N-acetyl-cysteine versus placebo

P Das, M Tanious, K Fritz, S Dodd, O Dean, M Berk, G Malhi

(2013), Vol. 47, pp. 347-354, Australian and New Zealand journal of psychiatry, London, England, C1

journal

A preliminary investigation on the efficacy of N-acetyl cysteine for mania or hypomania

P Vieira da Silva Magalhaes, O Dean, A Bush, D Copolov, G Malhi, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, M Berk

(2013), Vol. 47, pp. 564-568, Australian and New Zealand journal of psychiatry, London, England, C1

journal

Aspirin : a review of its neurobiological properties and therapeutic potential for mental illness

M Berk, M Berk, O Dean, O Dean, H Drexhage, H Drexhage, J McNeil, J McNeil, S Moylan, S Moylan, A O'Neil, A O'Neil, C Davey, C Davey, L Sanna, L Sanna, M Maes, M Maes

(2013), Vol. 11, pp. 1-17, BMC medicine, London, England, C1

journal

A randomised, controlled trial of a dietary intervention for adults with major depression (the 'SMILES' trial): study protocol

A O'Neil, M Berk, C Itsiopoulos, D Castle, R Opie, J Pizzinga, L Brazionis, A Hodge, C Mihalopoulos, M Chatterton, O Dean, F Jacka

(2013), Vol. 13, pp. 1-7, BMC psychiatry, London, England, C1

journal

The chemistry and biological activities of N-acetylcysteine

Y Samuni, S Goldstein, O Dean, M Berk

(2013), Vol. 1830, pp. 4117-4129, Biochim biophys acta, Amsterdam, Netherlands, C1

journal
2012

Systemic illness moderates the impact of N-acetyl cysteine in bipolar disorder

P Magalhaes, O Dean, A Bush, D Copolov, D Weisinger, G Malhi, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, M Berk

(2012), Vol. 37, pp. 132-135, Progress in neuro-psychopharmacology and biological psychiatry, Philadelphia, Pa., C1

journal

Minocycline : therapeutic potential in psychiatry

O Dean, J Data-Franco, F Giorlando, M Berk

(2012), Vol. 26, pp. 391-401, CNS Drugs, Auckland, New Zealand, C1

journal

Maintenance N-acetyl cysteine treatment for bipolar disorder : a double-blind randomised placebo controlled trial

M Berk, O Dean, S Cotton, C Gama, F Kapczinski, B Fernandes, K Kohlmann, S Jeavons, K Hewitt, K Moss, C Allwang, I Schapkaitz, H Cobb, A Bush, S Dodd, G Malhi

(2012), Vol. 10, pp. 1-11, BMC medicine, London, England, C1

journal

Adjunctive antioxidants for bipolar disorder

P Magalhaes, O Dean, A Andreazza, M Berk, F Kapczinski

(2012), pp. 1-11, The Cochrane collaboration, Oxford, England, C1-1

journal

Effects of N-acetyl cysteine on cognitive function in bipolar disorder

O Dean, A Bush, D Copolov, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, M Berk

(2012), Vol. 66, pp. 514-517, Psychiatry and clinical neurosciences, Richmond, Vic., C1

journal
2011

Qualitative methods in early-phase drug trials : data and methods from a trial of N-acetylcysteine in schizophrenia

M Berk, A Munib, O Dean, G Malhi, K Kohlmann, I Schapkaitz, S Jeavons, F Katz, M Anderson-Hunt, P Conus, B Hanna, R Otmar, F Ng, D Copolov, A Bush

(2011), Vol. 72, pp. 909-913, Journal of clinical psychiatry, [Memphis, Tenn.], C1-1

journal

N-acetylcysteine in psychiatry - current therapeutic evidence and potential mechanisms of action

O Dean, F Giorlando, M Berk

(2011), Vol. 36, pp. 78-86, Journal of psychiatry and neuroscience, Ottowa, Canada, C1-1

journal

N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and d-amphetamine-treated rats : relevance to schizophrenia and bipolar disorder

O Dean, M van den Buuse, M Berk, D Copolov, C Mavros, A Bush

(2011), Vol. 499, pp. 149-153, Neuroscience letters, Clare, Ireland, C1-1

journal

Role of dopamine D3 and serotonin 5-HT1A receptors in l-DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease

M Gerlach, G Bartoszyk, P Riederer, O Dean, M van den Buuse

(2011), Vol. 118, pp. 1733-1742, Journal of neural transmission, Amsterdam, The Netherlands, C1-1

journal

Antioxidant treatments for schizophrenia

P Magalhaes, A Andreazza, M Berk, F Kapczinski, O Dean

(2011), pp. 1-13, Cochrane database of systematic reviews, Oxford, U. K., C1-1

journal

N-acetyl cysteine add-on treatment for bipolar II disorder : a subgroup analysis of a randomised placebo-controlled trial

P Magalhães, O Dean, A Bush, D Copolov, G Malhi, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, M Berk

(2011), Vol. 129, pp. 317-320, Journal of affective disorders, Amsterdam, The Netherlands, C1-1

journal

Dimensions of improvement in a clinical trial of N-acetyl cysteine for bipolar disorder.

P Magalhães, O Dean, A Bush, D Copolov, G Malhi, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, M Berk

(2011), Vol. 23, pp. 87-88, Acta neuropsychiatrica, Oxford, England, C1-1

journal

Pathways underlying neuroprogression in bipolar disorder : focus on inflammation, oxidative stress and neurotrophic factors

M Berk, F Kapczinski, A Andreazza, O Dean, F Giorlando, M Maes, M Yücel, C Gama, S Dodd, B Dean, P Magalhães, P Amminger, P McGorry, G Malhi

(2011), Vol. 35, pp. 804-817, Neuroscience & biobehavioral reviews, Oxford, England, C1-1

journal

The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial

Michael Berk, Olivia Dean, Sue Cotton, Clarissa Gama, Flavio Kapczinski, Brisa Fernandes, Kristy Kohlmann, Susan Jeavons, Karen Hewitt, Christine Allwang, others

(2011), Vol. 135, pp. 389-394, Journal of affective disorders, C1

journal

Who's left? Symptoms of schizophrenia that predict clinical trial dropout

J Thompson, M Berk, O Dean, K Kohlmann, S Jeavons, A Bush, D Copolov

(2011), Vol. 26, pp. 609-613, Human psychopharmacology, West Sussex, England, C1-1

journal

N-acetylcysteine for major depressive episodes in bipolar disorder

P Magalhães, O Dean, A Bush, D Copolov, G Malhi, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, M Berk

(2011), Vol. 33, pp. 374-378, Revista Brasileira de Psiquiatria, Sao Paulo, Brazil, C1

journal
2010

Effects of n-acetyl-cysteine treatment on glutathione depletion and a short-term spatial memory deficit in 2-cyclohexene-1-one-treated rats

K Choy, O Dean, M Berk, A Bush, M van den Buuse

(2010), Vol. 649, pp. 224-228, European journal of pharmacology, Amsterdam, The Netherlands, C1-1

journal

Interaction of glutathione depletion and psychotropic drug treatment in prepulse inhibition in rats and mice

O Dean, A Bush, M Berk, D Copolov, M van den Buuse

(2010), Vol. 97, pp. 293-300, Pharmacology, biochemistry and behavior, Philadelphia, Pa., C1-1

journal

Oxidative pathways as a drug target for the treatment of autism

K Villagonzalo, S Dodd, O Dean, K Gray, B Tonge, M Berk

(2010), Vol. 14, pp. 1301-1310, Expert opinion on therapeutic targets, London, England, C1-1

journal

The validity and internal structure of the bipolar depression rating scale (BDRS): data from a clinical trial of N-acetylcysteine as adjunctive therapy in bipolar disorder

M Berk, S Dodd, O Dean, K Kohlmann, L Berk, G Malhi

(2010), Vol. 22, pp. 237-242, Acta neuropsychiatrica, Oxford, England, C1-1

journal
2009

Nail-biting stuff? The effect of N-acetyl cysteine on nail-biting

M Berk, S Jeavons, O Dean, S Dodd, K Moss, C Gama, G Malhi

(2009), Vol. 14, pp. 357-360, CNS spectrums, New York, N.Y., C1-1

journal

Glutathione depletion in the brain disrupts short-term spatial memory in the Y-maze in rats and mice

O Dean, A Bush, M Berk, D Copolov, M van den Buuse

(2009), Vol. 198, pp. 258-262, Behavioural brain research, Amsterdam, The Netherlands, C1-1

journal

A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice.

O Dean, M van den Buuse, A Bush, D Copolov, F Ng, S Dodd, M Berk

(2009), Vol. 16, pp. 2965-2976, Current medicinal chemistry, Schiphol, The Netherlands, C1-1

journal

Effects of N-acetylcysteine on substance use in bipolar disorder : a randomized placebo controlled clinical trial

M Bernardo, S Dodd, C Gama, D Copolov, O Dean, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, A Bush, M Berk

(2009), Vol. 21, pp. 239-245, Acta neuropsychiatrica, Oxford, England, C1-1

journal
2008

N-acetyl cysteine for depressive symptoms in bipolar disorder - a double blind, randomized, placebo-controlled trial

M Berk, D Copolov, O Dean, K Lu, S Jeavons, I Schapkaitz, M Anderson-Hunt, A Bush

(2008), Vol. 64, pp. 468-475, Biological psychiatry, Philadelphia, Pa., C1-1

journal

N-Acetyl cysteine as a glutathione precursor for schizophrenia : a double blind, randomized, placebo-controlled trial

M Berk, D Copolov, O Dean, K Lu, S Jeavons, I Schapkaitz, M Anderson-Hunt, F Judd, F Katz, P Katz, S Ording-Jespersen, J Little, P Conus, M Cuenod, K Do, A Bush

(2008), Vol. 64, pp. 361-368, Biological psychiatry, Philadelphia, Pa., C1-1

journal

Glutathione : a novel treatment target in psychiatry

M Berk, F Ng, O Dean, S Dodd, A Bush

(2008), Vol. 29, pp. 346-351, Trends in pharmacological sciences, London, England, C1-1

journal

Oxidative stress in psychiatric disorders : evidence base and therapeutic implications

F Ng, M Berk, O Dean, A Bush

(2008), Vol. 11, pp. 851-876, International journal of neuropsychopharmacology, Cambridge, England, C1-1

journal

N-acetylcysteine for antioxidant therapy : pharmacology and clinical utility

S Dodd, O Dean, D Copolov, G Malhi, M Berk

(2008), Vol. 8, pp. 1955-1962, Expert opinion on biological therapy, London, England, C1-1

journal

N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial

M Berk, D Copolov, O Dean, K Lu, S Jeavons, I Schapkaitz, M Anderson-Hunt, F Judd, F Katz, P Katz, S Ording-Jespersen, J Little, P Conus, M Cuenod, K Do, A Bush

(2008), Vol. 64, pp. 361-368, Biological Psychiatry, Philadelphia, Pa., C1-1

journal
2004

A pilot randomized, double-blind, placebo-controlled study of granisetron in the treatment of sexual dysfunction in women associated with antidepressant use

S Jespersen, M Berk, C Van Wyk, O Dean, S Dodd, C Szabo, C Maud

(2004), Vol. 19, pp. 161-164, International clinical psychopharmacology, Philadelphia, Pa., C1-1

journal

Funded Projects at Deakin

Australian Competitive Grants

The Efficacy of N-acetylcysteine as an Adjunctive Treatment in Bipolar Depression: A Double-blind, Randomised, Placebo-controlled Trial

Prof Michael Berk, Dr Olivia Dean, A/Prof Susan Cotton, Dr Seetal Dodd, Prof Gin Malhi, A/Prof Chee Ng

NHMRC Project Grant

  • 2015: $69,545
  • 2014: $169,437
  • 2013: $74,883
  • 2012: $197,858

The Efficacy of N-acetylcysteine as an adjunctive treatment in unipolar depression

Prof Michael Berk, Prof Gin Malhi, Dr Seetal Dodd, Dr Olivia Dean

NHMRC Project Grant

  • 2012: $32,725
  • 2011: $48,924

Proof of principle of the inflammatory and oxidative theory of depression: A treatment study

Prof Michael Berk, Dr Andrew Chanen, Ms Susan Harrigan, Mr Christopher Davey, Dr Sarah Hetrick, Dr Olivia Dean, Dr Seetal Dodd

NHMRC Project Grant

  • 2017: $99,805
  • 2016: $152,181
  • 2015: $110,745
  • 2014: $111,704
  • 2013: $105,227
  • 2012: $26,547

The efficacy of adjunctive Garcinia mangostana Linn. pericarp for bipolar depression: A 24-week double-blind, randomized, placebo-controlled trial.

Dr Olivia Dean, Prof Michael Berk, A/Prof Chee Ng, Dr Seetal Dodd, Prof Malcolm Hopwood, Dr Alyna Turner, Prof Felice Jacka

NHMRC Project Grant

  • 2017: $161,987

The N-ICE trial: A randomised controlled trial of the safety and efficacy of N-Acetyl Cysteine (NAC) as a pharmacotherapy for methamphetamine ('ice'¿) dependence

A/Prof Rebecca McKetin, Dr Olivia Dean, Prof Dan Lubman, Prof Paul Dietze, Dr Peter Higgs, Dr Peter Kelly, Dr Alyna Turner, Dr Brendan Quinn, Prof Greg Carter

NHMRC Project Grant

  • 2017: $47,906

Other Public Sector Funding

Refrigerated Centrifuge and Vortex

Prof Michael Berk, Dr Olivia Dean

  • 2015: $8,187

Industry and Other Funding

Efficacy of N-Acetyl Cysteine in Autism: A double blind, placebo-controlled randomised trial

Prof Michael Berk, Dr Seetal Dodd, Dr Olivia Dean, Dr Katherine Gray, Prof Bruce Tonge

  • 2013: $143,821
  • 2012: $119,640

The Efficacy of Minocycline as an Adjunctive Treatment in Unipolar Depression: A Pilot Study

Dr Olivia Dean

  • 2014: $10,000
  • 2013: $10,000
  • 2012: $10,000

The efficacy of minocycline as an adjunctive therapy for unipolar depression: A pilot study.

Dr Olivia Dean

  • 2014: $35,973
  • 2013: $13,966

The efficacy of adjunctive Garcinia mangostana Linn (mangosteen) pericarp for the treatment of Schizophrenia: A double-blind, randomized, placebo controlled trial.

Prof Michael Berk, Dr Seetal Dodd, Dr Olivia Dean, Dr Alyna Turner, A/Prof Susan Cotton, Prof John McGrath, Dr Frances Dark, A/Prof James Scott

  • 2017: $256,278
  • 2016: $239,559

Exploring inflammation in depression ¿ Minocycline compared with N-acetyl cysteine.

Dr Olivia Dean

  • 2017: $10,000
  • 2016: $20,000

The efficacy of adjunctive Garcinia mangostana linn (mangosteen) pericarp for bipolar depression: A 24-week double-blind, randomised, placebo controlled trial

Dr Olivia Dean, Miss Melanie Ashton

  • 2017: $4,250
  • 2016: $30,000

The efficacy of adjunctive Garcinia mangostana linn (mangosteen) pericarp for bipolar depression: A 24-week double-blind, randomised, placebo controlled trial

Dr Olivia Dean, Prof Michael Berk, Miss Melanie Ashton

  • 2017: $8,886
  • 2016: $3,863

Can we reduce tobacco smoking using N-acetylcysteine as a cessation treatment?

Prof Michael Berk, Dr Seetal Dodd, Dr Olivia Dean

  • 2017: $25,000

Supervisions

No completed student supervisions to report